fda removes semaglutide from shortage list ends shortage, closing the door on compounded Wegovy, Ozempic Hims & Hers stock falls

GIP is responsible for your pancreas release of glucagon, which acts as a check against insulin and may improve blood sugar balance in conjunction with GLP-1 RA activity.8 Research indicates that this combination works better than GLP-1 RAs alone in pursuit of weight loss

[1] [2] These mechanisms can indirectly contribute to symptoms such as dizziness, especially during the initial weeks of treatment or following dose escalation

But it may not be right for everyone

The 10 mg group achieved 19.5%

Specifically, 30.81% of participants receiving semaglutide experienced GI issues, while only 12.7% in the control group did